Cyclophosphamide trials for Pancreatic cancer

All Cyclophosphamide trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Pancreatic cancer

• A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
  NCT06898385 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
  NCT03190941 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
  NCT06885697 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
  NCT07523529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
  NCT06782932 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
  NCT01174121 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
  NCT04146298 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Cyclophosphamide for Pancreatic cancer?

9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.